Výsledky vyhledávání - "Robert J. Riley"

The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development

Autor: Stephanie Ryder, Clive Dilworth, Robert J. Riley, Paul Walker, Andrea Lavado

Publikováno v: Archives of Toxicology

Early identification of toxicity associated with new chemical entities (NCEs) is critical in preventing late-stage drug development attrition. Liver injury remains a leading cause of drug failures in clinical trials and post-approval withdrawals refl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df1118d3b609249f7a5fa9be40580cda
http://europepmc.org/articles/PMC7395068

Zobrazit plný text záznamu

Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS

Autor: Adam King, Lee A. Gethings, Ian D. Wilson, Robert S. Plumb, Lauren Mullin, Robert J. Riley, Billy J. Molloy

The metabolism and pharmacokinetics of gefitinib (Iressa®, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholino-propoxy)quinazolin-4-amine), a selective thymidylate kinase inhibitor for the epidermal growth factor receptor (EGFR), was studied after

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ae9f389da99895e4846cda72766c338

Zobrazit plný text záznamu

The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice

Autor: K. Schreiter, Ian D. Wilson, E. M. Wilson, J. Bial, A. P. Dickie, Claire E. Wilson, Robert J. Riley, Nico Scheer, R. Wehr

Publikováno v: Archives of Toxicology. 92:1953-1967

The pharmacokinetics of diclofenac were investigated following single oral doses of 10 mg/kg to chimeric liver humanized and murinized FRG and C57BL/6 mice. In addition, the metabolism and excretion were investigated in chimeric liver humanized and m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::297561bdf1d7267e4ca81fd633e73547
https://doi.org/10.1007/s00204-018-2212-1

Zobrazit plný text záznamu

Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery

Autor: Joanne L. Sproston, Robert J. Riley, Patrick Barton, Adam J. Lucas

Publikováno v: Expert opinion on drug discovery. 14(12)

Introduction: Prediction of human absorption, distribution, metabolism, and excretion (ADME) properties, therapeutic dose and exposure has become an integral part of compound optimization in discov...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a731e8df3343044b2bfd5ec41234c585
https://pubmed.ncbi.nlm.nih.gov/31538500

Zobrazit plný text záznamu

Hepatic drug transporters: the journey so far

Autor: S A Foley, Robert J. Riley, Matthew G. Soars, Beth Williamson, P Barton

Publikováno v: Expert Opinion on Drug Metabolism & Toxicology. 12:201-216

The key role of transporter biology in both the manifestation and treatment of disease is now firmly established. Experiences of sub-optimal drug exposure due to drug-transporter interplay have supported incorporation of studies aimed at understandin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5adede26936155a26e5bd682b90e295e
https://doi.org/10.1517/17425255.2016.1132308

Zobrazit plný text záznamu

A new paradigm for navigating compound property related drug attrition

Autor: Patrick Barton, Robert J. Riley

Publikováno v: Drug Discovery Today. 21:72-81

Improving the efficiency of drug discovery remains a major focus for the pharmaceutical industry. Toxicity accounts for 90% of withdrawals and major early-stage terminations relate to suboptimal efficacy and safety. Traditional oral drug space is wel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e69684934cdac87f6edc9fee1abf3f85
https://doi.org/10.1016/j.drudis.2015.09.010

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání